{"entity":{"id":"nct04986423","kind":"trial","name":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer","aka":[],"tldr":"A phase 2 trial of ZEN-3694, Enzalutamide in prostate cancer, run by Zenith Epigenetics, now recruiting.","summary":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT04986423 by Zenith Epigenetics, with 200 participants planned, started 2021-09-08 and due to reach its primary completion in 2026-12. Interventions recorded: ZEN003694, Enzalutamide. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04986423","url":"https://clinicaltrials.gov/study/NCT04986423"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["zen-3694","enzalutamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04986423","phase":"2","setting":"A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Zenith Epigenetics","enrolled":200,"outcomes":[]},"route":"/trials/nct04986423/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"zen-3694","kind":"drug","name":"ZEN-3694","route":"/drugs/zen-3694/"}]}}